Expand LGVN Menu
LGVN MENU

LGVN Latest Press Releases

-- April 8, 2026 --

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) Globe Newswire 9:15 AM

-- March 18, 2026 --

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed Globe Newswire 11:30 AM

-- March 17, 2026 --

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- March 12, 2026 --

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 Globe Newswire 9:00 AM

-- March 11, 2026 --

Longeveron Announces Closing of Private Placement of up to $30 Million Globe Newswire 4:05 PM

-- March 10, 2026 --

Longeveron Announces Private Placement of up to $30 Million Globe Newswire 9:00 AM

-- February 25, 2026 --

Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell Globe Newswire 11:05 AM

-- February 13, 2026 --

Longeveron Appoints Stephen H. Willard as Chief Executive Officer Globe Newswire 4:30 PM

-- February 5, 2026 --

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program Globe Newswire 9:15 AM

-- January 29, 2026 --

Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) Globe Newswire 9:15 AM

-- January 26, 2026 --

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 9:15 AM

-- December 29, 2025 --

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 Globe Newswire 9:15 AM

-- December 17, 2025 --

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy Globe Newswire 9:15 AM

-- December 3, 2025 --

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum Globe Newswire 9:15 AM

-- December 2, 2025 --

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging Globe Newswire 9:15 AM

-- December 1, 2025 --

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) Globe Newswire 12:00 PM

-- November 19, 2025 --

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) Globe Newswire 9:15 AM

-- November 12, 2025 --

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy Globe Newswire 9:05 AM
Market Data Delayed 15 Minutes